BMSD : 10.65048
BMSD : 10.65048
https://doi.org/10.65048/ijbmr
Search
About Us
Authors
Reviewers
Editorial Board
Contact Us

International Journal of Biological and Medical Research (IJBMR)

Review Article
Year : 2026  |  Volume : 17  |  Issue : 3  |  Page : 8725-8732 Full Version
Anticancer studies on dodonaea viscosa: a systematic review
Int J Biol Med Res. 2026; 17(3): 8725-8732  |  DOI: 10.65048/ijbmr.2026.17.3.8725.1078
Daniel Tyoapine1*, Timothy Bulus², Peter Waziri², Chinecherem Victory Promise³
¹Biotechnology Department, Kaduna State University, P.M.B. 2339, Kaduna, Nigeria
²Biochemistry Department, Kaduna State University, P.M.B. 2339, Kaduna, Nigeria
³Biotechnology Department, Nigerian Defence Academy, P.M.B. 2109, Kaduna, Nigeria.
Correspondence Address :
Daniel Tyoapine,
Biotechnology Department,
Kaduna State University, P.M.B. 2339,
Kaduna, Nigeria E-mail: tyoapinedaniel98@gmail.com
Received: March 7, 2026 Accepted: May 28, 2026 Published: July 3, 2026

Abstract
Cancer remains a leading cause of mortality worldwide, contributing to significant global morbidity with nearly 10 million deaths recorded in 2020. Despite advancements in conventional treatments, the burden of cancer persists due to high treatment costs, severe side effects, and the emergence of multidrug resistance, prompting interest in alternative therapies, particularly natural products derived from medicinal plants. Among these, Dodonaea viscosa, a member of the Sapindaceae family, has been widely utilized in traditional medicine for various ailments. A comprehensive literature search across Google Scholar, ScienceDirect, and PubMed identified 831 articles, with 19 studies selected based on predefined criteria related to anticancer effects. Critical review of the literature showed that D. viscosa has exhibited cytotoxic effects against multiple cancer types, including breast, colorectal, lung, liver, ovarian, leukemia, prostate, cervical, pancreatic, ehrlich ascites carcinoma, and laryngeal cancers. While in vitro studies provide compelling evidence of its cytotoxic potential, the review shows a critical gap in assessment of the selectivity and safety of the plant extracts, mechanistic studies, and in vivo research, presenting the need for further preclinical and clinical investigations to validate the efficacy of D. viscosa as a complementary therapeutic agent in oncology.
Keywords
Anticancer activity, Dodonaea viscosa, Natural products

Introduction

Among the top 10 most pressing global health challenges, cancer remains one [1], significantly contributing to morbidity and mortality, with nearly 10 million deaths recorded in 2020, approximately one in six deaths worldwide[2]. Despite advancements in conventional treatment options such as chemotherapy, radiotherapy, immunotherapy, and targeted therapy, cancer continues to pose challenges due to high treatment costs, severe side effects, and the emergence of multidrug resistance[3]. These limitations have driven the search for alternative or complementary therapies, with natural products playing important role in modern drug discovery[4, 5]. For a long while, medicinal plants have beenstudiedfor their therapeutic potential, as they offer diverse bioactive compounds with promising pharmacological effects[6, 7]. Several plant-derived compounds, including paclitaxel [8], vinblastine [9], camptothecin[10] and etoposide [11], have been successfully integrated into anticancer treatment regimens, demonstrating the potential of plant-based medicine in oncology[12].

Among the many medicinal plants under investigation, Dodonaea viscosa, a species belonging to the Sapindaceae family (Figure 1), has equally been under extensive ethnomedicinal applications. This hardy, evergreen shrub is widely distributed across tropical and subtropical regions, including Asia, Africa, Australia, and the Americas[13]. Traditionally, different parts of D. viscosa, including its leaves, stems, flowers, and roots, have been used to treat a range of ailments, such as wounds, fever, pain, gastrointestinal disorders, and inflammatory conditions[14, 15]. In recent years, scientific interest in D. viscosa has grown due to its rich phytochemical composition, which includes flavonoids, terpenoids, phenolic acids, alkaloids, tannins, and saponins[16, 17]. These bioactive constituents have been associated with diverse pharmacological activities, including antimicrobial, anti-inflammatory, antioxidant, and cytotoxic properties, making D. viscosa a promising candidate for anticancer research[18].

Given the increasing interest in plant-derived anticancer compounds, it is needful to do a comprehensive assessment of the anticancer activity of D. viscosa. This review aims to provide an in-depth evaluation of the available literature on the anticancer properties of D. viscosa, focusing on its potential as a complementary or alternative therapeutic agent in oncology. By consolidating existing scientific findings, this review seeks to bridge the gap between traditional medicinal knowledge and modern cancer research, providing insights for future directions for the development of plant-based anticancer agents.

 

Figure 1: Dodonaea viscosa (L.) Jacq.Plant

Materials and Method

A comprehensive literature search was conducted across three major scientific databases: Google Scholar, ScienceDirect, and PubMed. The search strategy included the keywords “Dodonaea viscosa” OR “Dodonea viscosa” OR “Hop bush” to retrieve relevant studies on the anticancer properties of D. viscosa. This initial search yielded a total of 830 articles, with 414 from Google Scholar, 270 from ScienceDirect, and 147 from PubMed. To ensure relevance, articles were screened based on predefined inclusion and exclusion criteria. Studies were included if they (i) specifically investigated the anticancer properties of D. viscosa, (ii) reported in vitro or in vivo experimental data related to anticancer activity. Articles were excluded if they (i) lacked anticancer relevance, (ii) focused solely on non-malignant diseases, or (iii) were review papers without original data. Following a thorough evaluation, a final set of 19 unique articles were selected for this review. These studies encompass mainly cytotoxic effects of D. viscosaagainst cancer cell lines. The selected articles provide the foundation for this comprehensive assessment of D. viscosa as a potential anticancer agent.

Results

Description of cancer studies on Dodonaea viscosa

Figure 2 shows a general analysis of the 19 selected studies on anticancer properties of Dodonaea viscosa. Most studies (18 out of 19) were in vitro, with only one in vivo study, indicating a focus on cell-based experiments. D. viscosa was most frequently studied against breast (8 studies), colorectal (6), lung cancer (5), and liver cancer (5) while other cancer types had limited representation. Crude extracts were used in 14 studies, while isolated compounds appeared in 5 studies, showing a preference for whole-plant extracts. Geographically, India (7 studies) contributed the most, with additional studies from Peru, Madagascar, Iraq, Pakistan, Egypt, Saudi Arabia, South Africa, Kenya and Nigeria. Only 2 studies conducted but little mechanistic analysis, suggesting a gap in understanding the exact mode of action of D. viscosa. Nanoparticles were used in 6 studies, while 13 studies did not explore nanotechnology-based approaches.

Figure 2: Overview of selected studies on the anticancer properties of Dodonaea viscosa

Anticancer activity of Dodonaea viscosa on various cancers

As summarized in Table 1, D. viscosa has exhibited promising anticancer activity against multiple cancers by inhibiting proliferation, inducing apoptosis, and modulating key pathways.

Breast cancer

According to WHO data, breast cancer has become the most common cancer diagnosed worldwide [19, 20]. It is a highly heterogeneous disease influenced by genetic, hormonal, and environmental factors [21, 22]. A couple of in vitro studies have reported the anticancer potential of Dodonaea viscosa against breast cancer cell lines. Studies by [15] investigated the cytotoxic effects of an 80% ethanolic extract of D. viscosa flowers against MCF-7 breast cancer cells, reporting a potent cytotoxic activity with an IC50 of 19.4 µg/mL, indicating significant inhibition of cell proliferation. Similarly, [23] evaluated the hydroalcoholic extract of D. viscosa against MCF-7 cells, reporting cytotoxic effects with an IC50 of 75.26 µg/mL. The study suggested that oxidative stress induction and apoptosis were key mechanisms contributing to the cytotoxicity. Also,[24] identified bioactive compounds from D. viscosa, including oleanane-type triterpenoid saponins (dodoneasides A and B), which exhibited antiproliferative activity against the BT-549 breast cancer cell line. These compounds disrupted cancer cell growth and survival mechanisms, suggesting their potential as novel anticancer agents. A recent study by [25]equally assessed the cytotoxic potential of D. viscosa fractions on MDA-MB-231 triple-negative breast cancer cells. Among the tested fractions, the chloroform fraction exhibited the highest cytotoxic activity, with an IC50 value of 24.6 ± 0.4 µg/mL. The study also linked the cytotoxic effects to the presence of flavonoids, particularly quercetin and kaempferol, which were quantified using HPTLC techniques.In addition, a study on Kenyan populations of D. viscosa reported significant antiproliferative activity of crude extracts against breast cancer cell lines, further confirming its potential in cancer therapy [26]. The research highlighted variations in bioactive compound composition among different populations, indicating the influence of environmental factors on phytochemical production. Another study validated the medicinal potential of D. viscosa against MCF-7 cells using methanolic and chloroform extracts, demonstrating cytotoxic effects through MTT and Trypan Blue assays [27]. Notably, the chloroform extract exhibited greater phytochemical diversity and enhanced cytotoxic effects, thus confirming the therapeutic potential of D. viscosa in breast cancer treatment. Nanoparticle formulations of D. viscosahavealso been evaluated to enhance its anticancer efficacy. Using D. viscosa leaf extracts, [28] synthesized silver nanoparticles (AgNPs) and tested their cytotoxicity against MCF-7 breast cancer cells. The nanoparticles showed strong anti-proliferative activity, with significant inhibition of cancer cell viability. Innovatively,[29] also engineered single-walled carbon nanotube (SWCNT) nanocarriers conjugated with D. viscosa-derived bioactive compounds. The bio-conjugates were tested on MCF-7 and MDA-MB-231 breast cancer cell lines, demonstrating improved selectivity and enhanced cytotoxic effects compared to crude extracts alone. The study suggested that the increased efficacy was due to targeted cellular uptake via folate receptor-mediated endocytosis. Furthermore, [30] evaluated the effects of an aqueous extract of D. viscosa on MCF-7 breast cancer cells. The study reported a cytotoxic activity with an IC50 value of 10.7 ± 0.38 µg/mL, indicating significant inhibition of cancer cell proliferation. The anticancer effects were attributed to apoptosis induction and oxidative stress modulation. The study also noted that among several tested medicinal plants, D. viscosa had one of the lowest IC50 values, which meansit may have strong antiproliferative potential against breast cancer. Though there is a bit substantial in vitroanti-breast cancer report on D. viscosa, no in vivo studies have been reported to date.

Colorectal cancer

Colorectal cancer (CRC) is the third most commonly diagnosed malignances and accounts for approximately 1.9 million cancer cases each year (10% of all new cancer cases globally)[31]. The progression of CRC is equally influenced by genetic mutations, epigenetic alterations, and environmental factors[32, 33]. A few researches have highlighted the cytotoxic potential of D. viscosa against colorectal cancer cell lines. Research conducted by [23]revealedthat,hydroalcoholic extract of D. viscosa exhibited cytotoxic effects against HCT-116 colon cancer cells, with an IC50 60.43 ± 0.76 μg/mL. The anticancer activity of hydroalcoholic extract of D. viscosa was futher evaluated by [34]on SW480 and SW620 colorectal cancer cells. The extract led to mitochondrial membrane disruption, increased apoptotic markers, and cell cycle arrest at the Sub G0/G1 phase, indicating its ability to trigger intrinsic apoptotic pathways. The bioactive components of D. viscosa, including flavonoids and triterpenoid saponins, have been implicated in its cytotoxic activity. Dodoneasides A and B, oleanane-type triterpenoid saponins, isolated by [24] demonstrated potentantiproliferative effects against HCC-2998 colon cancer cells by interfering with tumor survival mechanisms.Moreover, advanced formulations of D. viscosa extracts have been explored to enhance their therapeutic potential. ZnO nanocomposites, synthesizedby [35]using D. viscosa extracts, were found to exhibit enhanced cytotoxicity against HCT-116 cells, with an IC50 of 29.07 ± 2.7 μg/mL. These findings suggest that nanotechnology-based modifications may improve the efficacy of plant-derived anticancer agents. Additionally, [36] tested different solvent fractions of D. viscosa against HT-29 colorectal cancer cells, identifying the ethanol and ethyl acetate fractions as the most potent. These fractions showedhigh cytotoxicity while minimallyaffecting the on non-tumorigenic 3T3 fibroblast cells, which suggestive of their potential for safer cancer therapy. A novel approach by [29] utilizing single-walled carbon nanotube (SWCNT) nanocarriers conjugated with bioactive compounds from D. viscosa demonstrated improved selectivity and cytotoxicity against HT-29 colorectal cancer cells, with folate receptor-mediated endocytosis enhancing targeted drug delivery. Also,another study by [30] evaluated the anticancer potential of an aqueous extract of D. viscosa against HT-29 colorectal cancer cells. The study reported a cytotoxic activity with an IC50 15.2 ± 0.55 µg/mL, indicating significant inhibition of cell proliferation. However, no in vivo studies found. Thus,in vivo studies will be essential to establish pharmacokinetics, bioavailability, and long-term safety, while nanotechnology-based formulations hold potential for optimizing therapeutic outcomes.

Ovarian cancer

Ovarian cancer remains the most lethal gynecological malignancy due to its asymptomatic progression and frequent emergence of resistance to conventional treatments [37]. Despite the approval of promising targeted therapy such as bevacizumab and PARP inhibitors, 5-year survival has not improved significantly [38]. Cytotoxic potential of D. viscosa against ovarian cancer cell lines has equally be reported. Study by [24] investigated an ethanol extract from the roots of D. viscosa, leading to the isolation of two novel oleanane-type triterpenoid saponins, dodoneasides A and B. These compounds exhibited strong antiproliferative activity against the A2780 ovarian cancer cell line, with IC50 of 0.79 and 0.70 µM, respectively. In another study,[39] synthesized silver nanoparticles (AgNPs) using D. viscosa leaf extract and evaluated their anticancer activity against the SK-OV-3 ovarian cancer cell line. The AgNPsshowed dose-dependent cytotoxicity, with an IC502.23 µg/mL. Additionally, the bioassay-guided fractionation of D. viscosa extracts revealed that the dichloromethane fraction had strong anticancer activity, which supports its potential as a source of therapeutic compounds and these findings indicate that both crude extracts and nanoparticle formulations of D. viscosa hold promise for ovarian cancer treatment. In vivo and clinical studies are necessary to confirm the safety and efficacy of D. viscosa-derived compounds as there are no such studies yet.

Prostate cancer

Among the most prevalent malignancies affecting men, prostate cancer is one, equally contributing to global cancer-related mortality[40]. Investigations into the anticancer effects of D. viscosa have also shown promising results against prostate cancer cells. The two novel oleanane-type triterpenoid saponins, dodoneasides A and B identified by [24] via bioassay-guided fractionation of ethanol root extract of D. viscosa were also found to exhibit strong antiproliferative effects against the DU145 prostate cancer cell line, with IC50 values comparable to conventional chemotherapy agents. A separate study by [26] examined the effects of D. viscosa extracts on prostate cancer models, specifically DU145 and PC-3 cell lines. The resultsshowed that the extract effectively inhibited cancer cell proliferation while promoting apoptosis. To enhance the therapeutic potential of D. viscosa, another researchfocused on nanoparticle-based formulationsdeveloped ZnO nanocomposites using D. viscosa extracts and tested their effects on prostate cancer cells. These nanocomposites showed increased cytotoxicity compared to crude plant extracts, with improved targeting of cancerous cells while minimizing toxicity to normal prostate epithelial cells [35]. Just as in the case of colorectal cancer, it may be that integrating nanotechnology with plant-derived compounds could significantly enhance treatment efficacy and bioavailability. Notably, there are no in vivo reports to back these findings.

Lung cancer

Lung cancer or bronchogenic carcinoma refers to tumors originating in the lung parenchyma or within the bronchi [41]. Ranked third in both cancer incidence/mortality, It continues to be a major public health issue, with non-small cell lung carcinoma (NSCLC) and small cell lung carcinoma (SCLC) being the most frequently diagnosed subtypes[42]. However, there are also several rare forms of lung carcinoma that present distinct diagnostic and treatment challenges. These uncommon variants often resemble the clinical features of the more prevalent subtypes, highlighting the importance of early recognition and prompt diagnosis to ensure effective patient care[43]. Two novel oleanane-type triterpenoid saponins, dodoneasides A and B, isolated by [24] when tested lung cancer cells (NSCLC NCI-H460) showed potent antiproliferative activity against the cell line, with IC50 values in the micromolar range. Further investigation by [44]found that, partially purified bioactive fractions from D. viscosa leaves (fractions Dv12 and Dv20) significantly inhibited A549 human lung adenocarcinoma cell proliferation in a dose-dependent manner. Similarly, silver nanoparticles (AgNPs) synthesized by [45] using D. viscosa leaf extracts showed potent inhibitory effects on A549 lung cancer cell proliferation with IC50 14 µg/mL. Another study by [39] also confirmed the efficacy of silver nanoparticles against lung cancer. Their study reported an IC50 of 1.73 µg/mL for A549 cells lower than the report of [39], indicating a stronger cytotoxic effect. Additionally, [25]also evaluated the cytotoxic effects of different fractions of D. viscosa, identifying the chloroform fraction as the most potent against A549 lung cancer cells. To date, no in vivo reports are available for anti-lung cancer effect of D. viscosa.

Cervical cancer

Cervical cancer, primarily driven by persistent human papillomavirus (HPV) infection, is the fourth most common cancer in women worldwide, with approximately 660,000 new cases and 350,000 deaths recorded in 2022 [46, 47]. The highest incidence and mortality rates occur in low- and middle-income countries, reflecting significant health inequities due to limited access to national HPV vaccination programs, cervical screening, treatment services, and the influence of social and economic determinants[46].Cytotoxicity effects of thehydroalcoholic extract of D. viscosa on HeLa cervical cancer cells as evaluated by [23] revealed IC50 of 72.12 ± 0.87 µg/mL, indicating moderate anticancer activity. Additionally, a recent study by Autaet al., (2024) showed lower IC50 values of 19.2 ± 1.55, 33.8 ± 4.32 and 12.8 ± 1.58µg/mL by hexane stem, chloroform leaves and methanol leaves extracts of D. viscosa respectively on HeLa cells[48].

Liver cancer

Liver cancer, another major global health concern is currently ranked eighth most common cancer and the fourth leading cause of cancer-related deaths according to latest GLOBOCAN report (2022) [49]. Hepatocellular carcinoma (HCC) is the predominant type, accounting for approximately 75%–85% of cases, alongside intrahepatic cholangiocarcinoma and other mixed types [50].A study by [51]reported that the ethanol and ethyl acetate (1:1) extract of D. viscosa stem and root exhibited significant antiproliferative activity, with an IC50 of 20 µg/mL on HepG2 cells. Additionally, the ZnO nanocomposites synthesized by [35] equally exhibited enhanced anticancer activity on HepG2 cells, with an IC50 of 16.4 ± 4 µg/mL. Aqueous extract of D. viscosaalso showed cytotoxic effect on HepG2 cells with IC50 of 14.9 ± 0.47 µg/mL, demonstrating significant inhibition of liver cancer cell proliferation[35]. The most recent study by [48] also reported cytotoxicity activities of the hexane stem, chloroform leaves and methanol leaves extracts on the HepG2 cells with IC50 values of 17.6 ± 1.18, 25.8 ± 0.41, and 20.2 ± 0.08µg/mL respectively. Further in vivo study may strengthen the evidence on the therapeutic potential of this plant on liver cancer.

Leukemia

Leukemia is a malignant disorder affecting blood and bone marrow, leading to the uncontrolled proliferation of abnormal leukocytes [52]. In the singular study conducted by [51],ethanol and ethyl acetate (1:1) extract of D. viscosa stem was reported to demonstrate significant antiproliferation against THP-1 leukemia cells with IC50 of 3.4 µg/mL, indicating promising activity against leukemia cells. No in vivo reports were found.

Ehrlich ascites carcinoma

Ehrlich Ascites Carcinoma (EAC) is an undifferentiated carcinoma widely used as a tumor model to evaluate the anticancer potential of therapeutic compounds due to its similarity to human tumors [53]. It is characterized by rapid proliferation, high transplantability, a short lifespan, and 100% malignancy, with no regression. Notably, EAC lacks tumor-specific transplantation antigen (TSTA), making it a reliable model for assessing the antitumor effects of various therapeutic agents [54]. Investigation of bioactive fractions obtained from supercritical fluid extraction (SCFE) of D. viscosa against EAC in mice revealed significant increase in lifespan (ILS%) of treated mice, with values reaching up to 52.35% compared to controls. Additionally, tumor growth delay (SGD) was observed, indicating inhibition of tumor progression [55].

Pancreatic cancer

Pancreatic cancer is an aggressive malignancy with a poor prognosis and limited treatment options [56]. The most common form, pancreatic ductal adenocarcinoma (PDAC), is highly persistent and resistant to treatment. Despite ranking fifteenth in global incidence, it is the ninth leading cause of cancer-related deaths, reflecting its significant lethality [49]. Aqueous extract of D. viscosa used by [30]against AsPC-1 pancreatic cancer cells exhibited strong cytotoxic effect with IC50 of 8.5 ± 0.37 µg/mL indicating potent antiproliferative activity against pancreatic cancer cells.Noin vivo studies reported so far.

Laryngeal cancer

Laryngeal cancer (LC) is the second most common malignancy in the upper aerodigestive tract, primarily affecting the voice box[57]. Major risk factors include smoking, alcohol consumption, and HPV infection[58]. Furthermore, [30] reported that the aqueous extract of D. viscosa where cytotoxic against HEp-2 laryngeal cancer cells with IC50 of 12.3 ± 0.42 µg/mL but no available in vivo reports yet.

Table 1: Anticancer activity of D. viscosa on various cancers

Cancer Type

Subject

Plant part

Solvent of extract

Model

IC50 or effect

Reference

Breast cancer

MCF-7

Leaves

Hydroalcoholic solution

In vitro

75.26 ± 0.45 μg/ml

[23]

MCF-7

Flowers

80% Ethanol

In vitro

19.4 μg/ml

[15]

MCF-7

Leaves

Ethanol

In vitro

0.39 μg/ml

[29]?

MDA-MB-231

Leaves

Ethanol

In vitro

0.47 μg/ml

[29]?

MCF-12A (Normal)

Leaves

Ethanol

In vitro

8.39 μg/ml

[29]

MDA-MB-231

Leaves

Methanol-crude, Hexane-fraction, Chloroform-fraction, Butanol-fraction

In vitro

Methanol Crude: 47.3 ± 1.7 µg/mL, Hexane: 36 ± 0.5 µg/mL, Chloroform: 24.6 ± 0.4 µg/mL, Butanol: 87.3 ± 1.6 µg/mL

[25]

MCF-7

Not specified

Ethanol/Aqueous/Methanol

In vitro

Cytotoxic effect

[28]

HCC1395

Root

no specified

In vitro

5.21 ± 0.0 µg/ml (Hautriwaic acid lactone (11)), 53.58 ± 0.1 µg/ml (Catechin), 98.15 ± 0.2 µg/ml (Crude, Coastal), 22.22 ± 0.06 µg/ml (Crude, Nanyuki)

[26]

MCF7

Aerial parts

Aqueous

In vitro

6.5 ± 0.18 μg/ml

[30]

MCF-7

Leaves

Methanol, Chloroform

In vitro

Cytotoxicity observed (MTT &Trypan Blue assays, no IC50 reported)

[27]

Colorectal Cancer

SW480

Leaves

70% Ethanol (Hydroethanolic)

In vitro

129.8 ± 2.78 µg/mL (24h), 37.0 ± 1.58 µg/mL (48h)

[34]

SW620

Leaves

70% Ethanol (Hydroethanolic)

In vitro

87.7 ± 3.11 µg/mL (24h), 28.2 ± 1.69 µg/mL (48h)

[34]

HT-29

Leaves

Ethanol, Chloroform, Ethyl Acetate, n-Butanol, Aqueous, n-Hexane

In vitro

10.52 µg/mL (Ethanol), 15.12 µg/mL (Chloroform), 38.52 µg/mL (Ethyl Acetate), 40.22 µg/mL (n-Butanol), 120.00 µg/mL (Aqueous), >250 µg/mL (n-Hexane)

[36]

HCT-116

Leaves

Hydroalcoholic solution

In vitro

60.43 ± 0.76 μg/ml

[23]

HCT-116

Leaves

Ethanol (95% v/v), petroleum ether, chloroform, methanol

In vitro

chloroform fraction (DC) = 39.8 ± 13 µg/mL, crude extract & other fractions (moderately cytotoxic)

[25]

HCT-116

Leaves

Chloroform + ZnO Nanocomposite

In vitro

Chloroform-ZnO Nanocomposite (DC-ZnO) = 29.07 ± 2.7 µg/mL

[25]?

HT-29

Leaves

Ethanol

In vitro

0.53 µg/mL

[27]?

HCT116

Aerial parts

Aqueous

In vitro

7.6 µg/mL

[30]?

Lung cancer

A549

Leaves

Ethanol

In vitro

30.25 µg/mL (Dv12 fraction), 31.25 µg/mL (Dv20 fraction)

[44]

A549 NSCLC

Leaves

Methanol, Acetone, Acetonitrile, Water

In vitro

14 μg/mL (Methanol-AgNPs), 3 μg/mL (Acetone-AgNPs), 80 μg/mL (Acetonitrile-AgNPs), 4 μg/mL (Water-AgNPs)

[45]

Lung A549

Leaves

Aqueous

In vitro

1.73 µg/mL

[39]?

A549 NSCLC

Leaves

Methanol, Acetone, Acetonitrile, Water

In vitro

4 μg/mL (Methanol-AuNPs), 60 μg/mL (Acetone-AuNPs), 8 μg/mL (Acetonitrile-AuNPs), 100 μg/mL (Water-AuNPs)

[45]

A549

Leaves

Methanol, Chloroform, Hexane, Butanol

In vitro

IC50 = 134.6 µg/mL (Crude methanol extract), 50 µg/mL (Chloroform, Hexane), 83.3 µg/mL (Butanol)

[25]?

Liver cancer

HepG2

Leaf

Acetone + Ethanol (AEA)

In vitro

20 µg/ml

[51]

HepG2

Stem

Water + Acetone (WA)

In vitro

> 20 µg/ml

[51]?

HepG2

Root

Ethanol + Ethyl Acetate (EEA)

In vitro

20 µg/ml

[51]?

HepG2

Leaves

Ethanol (95% v/v), petroleum ether, chloroform, methanol

In vitro

chloroform fraction (DC) = 26.4 ± 3.3 µg/mL, crude extract & other fractions (moderately cytotoxic)

[25]

HepG2

Leaves

Chloroform + ZnO Nanocomposite

In vitro

Chloroform-ZnO Nanocomposite (DC-ZnO) = 16.4 ± 4 µg/mL

[25]?

HepG2

Leaves

Methanol, Chloroform, Hexane, Butanol

In vitro

52.6 µg/mL (Chloroform), 60 µg/mL (Hexane), 94 µg/mL (Butanol), 137 µg/mL (Crude extract)

[25]?

HepG2

Aerial parts

Aqueous

In vitro

6.6 µg/mL

[25]?

HepG2

Stem

Hexane

In vitro

17.6 µg/mL

[48]

HepG2

Leaves

Chloroform, methanol

In vitro

25.8 µg/mL (chloroform), 20.2 µg/mL (methanol)

[48]

Ovarian Cancer

A2780

Roots

Ethanol (EtOH)

In vitro

Compound 1: 0.79 μM, Compound 2: 0.70 μM

[24]

SK-OV-3

Leaves

Aqueous

In vitro

2.23 µg/mL

[39]?

Leukemia

THP-1

Leaf

Water (W), Water + Methanol (WM)

In vitro

8.5 mg/ml (W), 11.5 mg/ml (WM)

[51]?

THP-1

Stem

Ethanol + Ethyl Acetate (EEA), Methanol + Ethyl Acetate (MEA)

In vitro

3.4 mg/ml (EEA), 3.8 mg/ml (MEA)

[51]?

THP-1

Root

Methanol + Chloroform (MC)

In vitro

9.4 mg/ml

[51]?

Prostate Cancer

DU 145

Leaves

Methanol-Dichloromethane (1:1), Ethyl Acetate (EtOAc)

In vitro

11.62 µg/ml (Methanol-Dichloromethane), 12.17 µg/ml (EtOAc)

[26]

Cervical cancer

HeLa

Leaves

Hydroalcoholic

In vitro

72.12 ± 0.87 μg/ml

[23]

HeLa

Stem

Hexane

In vitro

19.2 µg/mL

[48]

HeLa

Leaves

Chloroform, methanol

In vitro

33.8 µg/mL (chloroform), 12.8 µg/mL (methanol)

[48]

Pancreatic Cancer

AsPC-1

Aerial parts

Aqueous

In vitro

8.5 µg/mL

[30]

Laryngeal Cancer

HEP-2

Aerial parts

Aqueous

In vitro

6.0 µg/mL

[30]?

Ehrlich Ascites Carcinoma

EAC

Aerial parts

CO? (Supercritical Fluid Extraction (SCFE))

In Vivo

Increased lifespan (ILS%) at doses of 50 mg/kg (33.33%), 100 mg/kg (38.09%), and 200 mg/kg (52.38%); tumor volume reduction (SGD values: 0.66, 0.08, 0.29, 0.20)

[55]

Footnote: IC?? - half-maximal inhibitory concentration, MCF-7, MDA-MB-231, MCF-12A - breast cancer cell lines (MCF-12A normal breast cell line), SW480, SW620, HT-29, HCT-116 - colorectal cancer cell lines, A549 - lung cancer cell line, HepG2 - liver cancer cell line, NSCLC - non-small cell lung cancer, AgNPs - silver nanoparticles, AuNPs - gold nanoparticles, ZnO - zinc oxide, DC - Dodonaea chloroform, AEA - acetone + ethanol extract, WA - water + acetone extract, EEA - ethanol + ethyl acetate extract, MTT assay - 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay.

Mechanism of action of Dodonaea viscosa extracts

Two studies among the selected showed that the anticancer activity of D. viscosa involve apoptosis induction through mitochondrial dysfunction and key signaling pathways. Study by [34] which focused on colorectal cancer cells (SW480 and SW620) reported activation of caspase-3 and increase in p53 expression following treatment with hydroethanolic extract of D. viscosa, which suggest apoptosis was via the intrinsic (mitochondrial) pathway. Mitochondrial depolarization was also observed, while caspase-8 remained unaffected, indicating that apoptosis was not mediated by the extrinsic pathway. In leukemia cells, D. viscosa targeted pro-survival pathways by inhibiting Bcl-2 and PI3K/AKT signaling. This led to cytochrome c release, activation of caspase-9, and subsequent apoptosis via caspase-3. The presence of flavonoids, such as quercetin and rutin, likely contributed to these effects [29].

Research Gaps Identified

Most of the studies on Dodonaea viscosain this review have been limited to in vitro experiments, with only one in vivo study reported, making it difficult to confirm its real therapeutic potential in living systems. There is also a lack of detailed mechanistic studies explaining how the plant’s extracts exert anticancer effects across the cancers profiled at the molecular level. Additionally, only one study included a non-cancerous cell line as a control, limiting the assessment of the selectivity and safety of the extracts. The identified gaps present the need for well-designed mechanistic investigations, in vivo studies, and safety assessments to advance D. viscosa toward clinical relevance in cancer therapy.

Conclusions

Numerous studies have evaluated the potential anticancer effects of D. viscosa, revealing its ability to inhibit cancer cell proliferation and induce apoptosis in various cancer types. These studies demonstrated cytotoxic activity against multiple cancer cell lines, including Breast cancer, Colorectal cancer, Lung cancer, Liver cancer, Ovarian cancer, Leukemia, Prostate cancer, Cervical cancer, Pancreatic cancer, Laryngeal cancer, Ehrlich Ascites Carcinoma. The mechanisms underlying these effects as represented in few of the studies reviewed included apoptosis induction, and inhibition of key oncogenic signaling pathways. While in vitro studies provided compelling evidence of the cytotoxic potential of D. viscosa, in vivo research remains limited. There is therefore need for further preclinical and clinical investigations to establish D. viscosaas a viable anticancer agent.

Conflicts of Interest:

The Authors declares that they have no conflicts of interest to disclose.


References

[1]    Lucero?Prisno III, D.E., D.O. Shomuyiwa, M. Kouwenhoven, T. Dorji, Y.A. Adebisi, G.O. Odey, N.S. George, O.T. Ajayi, O. Ekerin, and E. Manirambona, Top 10 Public Health Challenges for 2024: Charting a New Direction for Global Health Security. Public Health Challenges, 2025. 4(1): p. e70022.

[2]    World Health Organization, Cancer. 2025.

[3]    Liu, B., H. Zhou, L. Tan, K.T.H. Siu, and X.-Y. Guan, Exploring treatment options in cancer: tumor treatment strategies. Signal transduction and targeted therapy, 2024. 9(1): p. 175.

[4]    Coy-Barrera, E., I.V. Ogungbe, and T.J. Schmidt, Natural Products for Drug Discovery in the 21st Century: Innovations for Novel Therapeutics. Molecules, 2023. 28(9): p. 3690.

[5]    Khoshnevisan, K., H. Alipanah, H. Baharifar, N. Ranjbar, and M. Osanloo, Chitosan nanoparticles containing cinnamomum verum J. Presl essential oil and cinnamaldehyde: preparation, characterization and anticancer effects against melanoma and breast cancer cells. Traditional and Integrative Medicine, 2022: p. 1-12.

[6]    Chaachouay, N. and L. Zidane, Plant-Derived Natural Products: A Source for Drug Discovery and Development. Drugs and Drug Candidates, 2024. 3(1): p. 184-207.

[7]    Dar, R.A., M. Shahnawaz, M.A. Ahanger, and I. Majid, Exploring the diverse bioactive compounds from medicinal plants: a review. J. Phytopharm, 2023. 12(3): p. 189-195.

[8]    Zhu, L. and L. Chen, Progress in research on paclitaxel and tumor immunotherapy. Cellular & molecular biology letters, 2019. 24(1): p. 40.

[9]    Paul, A., K. Acharya, and N. Chakraborty, Biosynthesis, extraction, detection and pharmacological attributes of vinblastine and vincristine, two important chemotherapeutic alkaloids of Catharanthus roseus (L.) G. Don: a review. South African Journal of Botany, 2023. 161: p. 365-376.

[10]    Behera, A. and S. Padhi, Passive and active targeting strategies for the delivery of the camptothecin anticancer drug: a review. Environmental Chemistry Letters, 2020. 18(5): p. 1557-1567.

[11]    Wu, C.-C., T.-K. Li, L. Farh, L.-Y. Lin, T.-S. Lin, Y.-J. Yu, T.-J. Yen, C.-W. Chiang, and N.-L. Chan, Structural basis of type II topoisomerase inhibition by the anticancer drug etoposide. Science, 2011. 333(6041): p. 459-462.

[12]    Chunarkar-Patil, P., M. Kaleem, R. Mishra, S. Ray, A. Ahmad, D. Verma, S. Bhayye, R. Dubey, H.N. Singh, and S. Kumar, Anticancer drug discovery based on natural products: From computational approaches to clinical studies. Biomedicines, 2024. 12(1): p. 201.

[13]    Muqaddas, R.A.K., A. Tahir, and F. Nadeem, Historical origin, chemical constituents and therapeutic potentials of sanatha (Dodonaea viscose)–A brief review. International Journal of Chemical and Biochemical Sciences, 2018. 14: p. 48-54.

[14]    Muhammad, A., G. Tel-Çayan, M. Öztürk, M.E. Duru, S. Nadeem, I. Anis, S.W. Ng, and M.R. Shah, Phytochemicals from Dodonaea viscosa and their antioxidant and anticholinesterase activities with structure–activity relationships. Pharmaceutical Biology, 2016. 54(9): p. 1649-1655.

[15]    Shafek, R.E., N.H. Shafik, H.N. Michael, A.M. El-Hagrassi, and A.F. Osman, Phytochemical studies and biological activity of Dodonaea viscosa flowers extract. Journal of Chemical and Pharmaceutical Research, 2015. 7(5): p. 109-116.

[16]    Beshah, F., Y. Hunde, M. Getachew, R.K. Bachheti, A. Husen, and A. Bachheti, Ethnopharmacological, phytochemistry and other potential applications of Dodonaea genus: A comprehensive review. Current Research in Biotechnology, 2020. 2: p. 103-119.

[17]    Bangajavalli, S., Pharmacognostical and Phytochemical Studies of Dodonaea viscosa (L).Jacq (Sapindaceae). International Research Journal of Plant Science, 2023. 14(2).

[18]    Riaz, M., R. Khalid, M. Afzal, F. Anjum, H. Fatima, S. Zia, G. Rasool, C. Egbuna, A.G. Mtewa, and C.Z. Uche, Phytobioactive compounds as therapeutic agents for human diseases: A review. Food science & nutrition, 2023. 11(6): p. 2500-2529.

[19]    Trapani, D., O. Ginsburg, T. Fadelu, N.U. Lin, M. Hassett, A.M. Ilbawi, B.O. Anderson, and G. Curigliano, Global challenges and policy solutions in breast cancer control. Cancer treatment reviews, 2022. 104: p. 102339.

[20]    Maleki, M., Z. Yazdiniapour, M. Ghanadian, B. Zolfaghari, F. Rabbani, and F. Shafiee, Cytotoxicity and apoptosis inducing effects of some lathyrane and tigliane diterpenes against breast cancer cell lines. Traditional and Integrative Medicine, 2021: p. 103-110.

[21]    Admoun, C. and H.N. Mayrovitz, The etiology of breast cancer. 2022.

[22]    Kunsti?, T.T., N. Debeljak, and K.F. Tacer, Heterogeneity in hormone-dependent breast cancer and therapy: Steroid hormones, HER2, melanoma antigens, and cannabinoid receptors. Advances in Cancer Biology-Metastasis, 2023. 7: p. 100086.

[23]    Ramkumar, R., S. Periyasamy, B. Venkatraman, and K. Sekar, In-vitro Anti-Cancer and Anti-Inflammatory Screening of Dodonaea viscosa. 2021.

[24]    Cao, S., P. Brodie, M. Callmander, R. Randrianaivo, J. Razafitsalama, E. Rakotobe, V.E. Rasamison, K. TenDyke, Y. Shen, and E.M. Suh, Antiproliferative triterpenoid saponins of Dodonaea viscosa from the Madagascar dry forest. Journal of natural products, 2009. 72(9): p. 1705-1707.

[25]    Almarfadi, O.M., N.A. Siddiqui, A.A. Shahat, A.S. Alqahtani, P. Alam, F.A. Nasr, S.S. Alshahrani, and O.M. Noman, Quantification of biomarkers and evaluation of antioxidant, anti-inflammatory, and cytotoxicity properties of Dodonaea viscosa grown in Saudi Arabia using HPTLC technique. Open Chemistry, 2022. 20(1): p. 559-569.

[26]    Kaigongi, M.M., Chemosystematics, Antimicrobial and Antiproliferative Activities of the Kenyan Zanthoxylum Species and Dodonaea Viscosa Populations. 2020, University of Nairobi.

[27]    Jayaraman, A., D.V. Karthikeyan, and M.C.A. Akilan. Antimicrobial, Antioxidant and Anticancerous Studies on Dodonaea Viscosa Leaf Extracts Against Human Breast Cancer Cell Line (MCF-7). 2021.

[28]    Giridharan, T., C. Masi, S. Sindhu, and P. Arumugam, Studies on green synthesis, characterization and anti-proliferative potential of silver nano particle using Dodonaea viscosa and Capparis decidua. Biosci. Biotechnol. Res. Asia, 2014. 11: p. 665-673.

[29]    Gwanzura, T., Engineering carbon nanotubes as therapeutic nanocarriers of Tulbaghia violacea, Annona muricata, Dicoma capensis and Dodonaea viscosa plant-based extracts, targeting breast and colorectal cancer. 2023, Stellenbosch: Stellenbosch University.

[30]    Alzandi, A.A., E.A. Taher, N.A. Al-Sagheer, A.W. Al-Khulaidi, M. Azizi, and D.M. Naguib, Phytochemical components, antioxidant and anticancer activity of 18 major medicinal plants in Albaha region, Saudi Arabia. Biocatalysis and Agricultural Biotechnology, 2021. 34: p. 102020.

[31]    Klimeck, L., T. Heisser, M. Hoffmeister, and H. Brenner, Colorectal cancer: A health and economic problem. Best Practice & Research Clinical Gastroenterology, 2023. 66: p. 101839.

[32]    Parmar, S. and H. Easwaran, Genetic and epigenetic dependencies in colorectal cancer development. Gastroenterology report, 2022. 10: p. goac035.

[33]    Duan, B., Y. Zhao, and J. Bai, Colorectal cancer: an overview, in gastrointestinal cancers. Brisbane (AU): JExon Publications, 2022.

[34]    Herrera-Calderon, O., A. Herrera-Ramírez, W. Cardona-G, E.J. Melgar-Merino, H. Chávez, J.B. Pari-Olarte, E. Loyola-Gonzales, J.F. Kong-Chirinos, J.S. Almeida-Galindo, and G. Peña-Rojas, Dodonaea viscosa Jacq. induces cytotoxicity, antiproliferative activity, and cell death in colorectal cancer cells via regulation of caspase 3 and p53. Frontiers in Pharmacology, 2023. 14: p. 1197569.

[35]    Alghamdi, M.D., S. Nazreen, N.M. Ali, and T. Amna, ZnO nanocomposites of Juniperus procera and Dodonaea viscosa extracts as antiproliferative and antimicrobial agents. Nanomaterials, 2022. 12(4): p. 664.

[36]    Herrera-Calderon, O., M.H. Rahman, G. Pena-Rojas, and V. Andia-Ayme, Dodonaea viscosa Jacq: a medicinal plant with cytotoxic effect on colon cancer cell line (HT-29). J. Pure Appl. Microbiol, 2020. 14: p. 1927-1934.

[37]    Arora, T., S. Mullangi, E.S. Vadakekut, and M.R. Lekkala, Epithelial ovarian cancer, in StatPearls [Internet]. 2024, StatPearls Publishing.

[38]    Hillmann, J., N. Maass, D.O. Bauerschlag, and I. Flörkemeier, Promising new drugs and therapeutic approaches for treatment of ovarian cancer—targeting the hallmarks of cancer. BMC medicine, 2025. 23(1): p. 10.

[39]    Al-Musawi, Z.F. and N.H. Al-Saadi, Antitumor activities of biosynthesized silver nanoparticles using Dodonaea viscosa (L.) leaves extract. Basrah Journal of Agricultural Sciences, 2021. 34(2): p. 42-59.

[40]    Leslie, S., T. Soon-Sutton, S.H. RIA, and W. Skelton, Prostate Cancer. 2023 Nov 13. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing, 2024.

[41]    Siddiqui, F., S. Vaqar, and A. Siddiqui, Lung Cancer. 2023 May 8. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing, 2023.

[42]    Leiter, A., R.R. Veluswamy, and J.P. Wisnivesky, The global burden of lung cancer: current status and future trends. Nature reviews Clinical oncology, 2023. 20(9): p. 624-639.

[43]    Singh, P., A.S. Vasan, K. Kumar, N.B. Ahuja, and M. Manoj, Beyond the Usual Suspects: A Case Series and Review of Rare Lung Carcinomas. Asian Pacific Journal of Cancer Care, 2024. 9(2): p. 391-394.

[44]    Priya, V.T., N. Balasubramanian, V. Shanmugaiah, P. Sathishkumar, N. Kannan, C. Karunakaran, A. Alfarhan, and P. Antonisamy, Partially purified lead molecules from Dodonaea viscosa and their antimicrobial efficacy against infectious human pathogens. Journal of Infection and Public Health, 2021. 14(12): p. 1822-1830.

[45]    Anandan, M., G. Poorani, P. Boomi, K. Varunkumar, K. Anand, A.A. Chuturgoon, M. Saravanan, and H.G. Prabu, Green synthesis of anisotropic silver nanoparticles from the aqueous leaf extract of Dodonaea viscosa with their antibacterial and anticancer activities. Process Biochemistry, 2019. 80: p. 80-88.

[46]    World Health Organization, Cervical cancer. 2024.

[47]    Cibula, D., M.R. Raspollini, F. Planchamp, C. Centeno, C. Chargari, A. Felix, D. Fischerová, D. Jahnn-Kuch, F. Joly, and C. Kohler, ESGO/ESTRO/ESP Guidelines for the management of patients with cervical cancer–Update 2023. Virchows Archiv, 2023. 482(6): p. 935-966.

[48]    Auta, R., P. Waziri, O.T. Oweh, S. Wayah, D. Tyoapine, M. Bobai, B. Solomon, and U. Onyemaobi, Antibacterial, anticancer and antioxidant properties of the stem and leaf extract of Dodonaea viscosa. Science World Journal, 2024. 20(1): p. 331-335.

[49]    International Agency for Research on Cancer [IARC], GLOBOCAN 2022: Cancer Today. Retrieved from https://bit.ly/43j3bdi. 2022.

[50]    Li, Q., M. Cao, L. Lei, F. Yang, H. Li, X. Yan, S. He, S. Zhang, Y. Teng, and C. Xia, Burden of liver cancer: From epidemiology to prevention. Chinese Journal of Cancer Research, 2022. 34(6): p. 554.

[51]    Malik, M.N., I.-u. Haq, H. Fatima, M. Ahmad, I. Naz, B. Mirza, and N. Kanwal, Bioprospecting Dodonaea viscosa Jacq.; a traditional medicinal plant for antioxidant, cytotoxic, antidiabetic and antimicrobial potential. Arabian Journal of Chemistry, 2022. 15(3): p. 103688.

[52]    Karunarathna, I., K. De Alvis, P. Gunasena, and A. Jayawardana, Leukemia: Classification, risk factors, and diagnostic challenges. 2024, ResearchGate. https://www. researchgate. net/publication ….

[53]    Ozaslan, M., I.D. Karagoz, I.H. Kilic, and M.E. Guldur, Ehrlich ascites carcinoma. African journal of Biotechnology, 2011. 10(13): p. 2375-2378.

[54]    Hashem, M.A., S.B. Shoeeb, Y.M. Abd-Elhakim, and W.A. Mohamed, The antitumor activity of Arthrospira platensis and/or cisplatin in a murine model of Ehrlich ascites carcinoma with hematinic and hepato-renal protective action. Journal of Functional Foods, 2020. 66: p. 103831.

[55]    Krupanidhi, A., P. Dabadi, J. Kulkarni, D. Ekbote, and P. Davan, Anti-neoplastic activities of targeted bio-moieties of Dodonaea Viscosa. World Journal of Pharmaceutical Sciences, 2018: p. 5-13.

[56]    Farhangnia, P., H. Khorramdelazad, H. Nickho, and A.-A. Delbandi, Current and future immunotherapeutic approaches in pancreatic cancer treatment. Journal of Hematology & Oncology, 2024. 17(1): p. 40.

[57]    Bulbulia, B. and M. Ahmed, Cancer of the Larynx: A Brief Overview with Case Studies. British Journal of Healthcare and Medical Research-Vol, 2024. 11(1).

[58]    Liberale, C., D. Soloperto, A. Marchioni, D. Monzani, and L. Sacchetto, Updates on larynx cancer: risk factors and oncogenesis. International journal of molecular sciences, 2023. 24(16): p. 12913.


IJBMR -ISSN: 0976:6685. ©Copyright 2026 This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Published by BioMedSciDirect Publications